Name:
GEN Biotechnology: 3 Minutes with Dr. Kevin Davies, Executive Editor
Description:
GEN Biotechnology: 3 Minutes with Dr. Kevin Davies, Executive Editor
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/7a3b5ca9-39fc-4d0b-bb93-57e9ee2f6804/videoscrubberimages/Scrubber_2.jpg?sv=2019-02-02&sr=c&sig=sjrPw9e89BuX8jQvwJvWrWzOPffVQFveJj8h%2BqXRgDc%3D&st=2025-05-11T14%3A28%3A12Z&se=2025-05-11T18%3A33%3A12Z&sp=r
Duration:
T00H04M19S
Embed URL:
https://stream.cadmore.media/player/7a3b5ca9-39fc-4d0b-bb93-57e9ee2f6804
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/7a3b5ca9-39fc-4d0b-bb93-57e9ee2f6804/GEN Biotechnology Interview Sept 2021-3.mp4?sv=2019-02-02&sr=c&sig=6ffX%2F57GI8kRHy2ekD1gQxMrj4YapEDg5lhT%2BECRB2E%3D&st=2025-05-11T14%3A28%3A12Z&se=2025-05-11T16%3A33%3A12Z&sp=r
Upload Date:
2023-10-19T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
[MUSIC PLAYING]
WENDY NEWSHAM: The idea of a peer-reviewed companion journal for Mary Ann Liebert's world-renowned biotechnology news resource GEN is absolutely brilliant. And I'm grateful that you can spend a few minutes elaborating on the importance of inclusion of the title in every research library's collection for 2022. Kevin, you were a founding director of Nature Genetics, so have had a significant impact in launching a pivotal biotechnology journal. And now you are leveraging your incredible expertise to launch this title.
WENDY NEWSHAM: What field or fields will GEN Biotechnology serve best?
KEVIN DAVIES: Thanks, Wendy. GEN Biotechnology will be a truly multidisciplinary journal, spanning the full breadth of innovative biotechnology from genomics and proteomics and next-gen sequencing, of course, cell and immunotherapy, and synthetic biology to drug development, cancer research, environmental and agricultural biotechnology, and I'm sure many other avenues that I haven't even explained just yet.
WENDY NEWSHAM: Terrific. And what gap does it fill in the scholarly journal space?
KEVIN DAVIES: Well, we looked at the biotechnology sector, which is what Mary Ann Liebert and genetic engineering news are all about and have been for 40 years and felt that there needed, there was room, there was a demand for a new marquee biotechnology journal, one that would truly capture the best of the dazzling research and investment that's going on in the biotech sector right now. So we're building on GEN's 40-year legacy covering the biotech industry.
KEVIN DAVIES: But now we're really putting a peer-review spin on it, a venue for exceptional research across all of the fields that I just mentioned. So I think by publishing indispensable research in basic, translational, and even clinical fields, this is a journal that researchers up and down the country and around the world are really going to need to have at their fingertips.
WENDY NEWSHAM: Yeah. And I've had a little peek behind the curtain and know that that is absolutely true. Would you also be willing to share with us why a corporation should make it available to its researchers?
KEVIN DAVIES: Well, I think, again, the compelling nature of the peer-review research, which is going to be we're going to place a premium on that in putting this journal out in 2022. But we'll be combining that with an array of commentary and analysis, biotech trends, KOL interviews and opinion pieces that I think will add immeasurably to the reader experience and make this, say, a must-have, must-read journal.
WENDY NEWSHAM: Fantastic. And finally, how does this journal compare to Nature Biotechnology?
KEVIN DAVIES: Yes, a journal I know well, having been in the offices at Nature Genetics when that journal was launched. That is a fabulous journal. But there is room for additional high-caliber, high-impact biotechnology research. And one of the key differentiators with GEN Biotechnology is that GEN Biotechnology will be led by a truly distinguished world-class academic and industry advisory board.
KEVIN DAVIES: And we've already named a few of the editors and editorial advisors who we will be working with to get the journal off the ground. Much more news on that to come in the weeks ahead.
WENDY NEWSHAM: Fabulous, Kevin. Thank you so much. As you know, I'm utterly thrilled about this title. And good luck on its launch. And we will talk to you soon.
KEVIN DAVIES: Thanks, Wendy.
WENDY NEWSHAM: Bye bye.
Form Title Download
Form Title Bookmark
Form Title Share
Form Title Cite
